| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/08/2002 | US20020106778 Human PTTG polypeptide and method for producing it |
| 08/08/2002 | US20020106746 Nucleotide sequences coding preferential protein for use in the treatment of septic shock, liver and immunological, tumors and connective tissue defects |
| 08/08/2002 | US20020106731 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of apoptosis and inflammation defects |
| 08/08/2002 | US20020106655 Nucleotide sequences coding preferential protein for use in the treatment, diagnosis and prevention of immunological, nervous system and tumor disorders |
| 08/08/2002 | US20020106650 Nucleotide sequence coding preferential polypeptide; for use in the treatment, prevention and diagnosis of kidney, liver, reproductive and cardiovascular disorders |
| 08/08/2002 | US20020106631 Recombinant, active caspases and uses thereof |
| 08/08/2002 | US20020106630 Method of identifying HIBEF51 receptor inhibitors |
| 08/08/2002 | US20020106359 Method and composition for treating prostate cancer |
| 08/08/2002 | US20020106356 Secreted proteins |
| 08/08/2002 | US20020106348 Contacting cell with agent that increases intracellular superoxide anion and contacting cell with 2-methoxyestradiol for killing a cell |
| 08/08/2002 | US20020106324 Treating cancer whereof the cells exhibit overexpression of a product of a gene of the myc-related family |
| 08/08/2002 | CA2444661A1 Use of cd23 antagonists for the treatment of neoplastic disorders |
| 08/08/2002 | CA2438594A1 Diazocine derivatives and their use as tryptase inhibitors |
| 08/08/2002 | CA2437555A1 Stabilised polymeric aerosols for pulmonary gene delivery |
| 08/08/2002 | CA2437044A1 Method of determining a chemotherapeutic regimen based on ercc1 expression |
| 08/08/2002 | CA2436774A1 Sulfonamide lactam inhibitors of factor xa |
| 08/08/2002 | CA2436748A1 Method of using a variant of vegf receptor to treat psoriasis and to enhance wound healing |
| 08/08/2002 | CA2436610A1 Protein kinase signalling |
| 08/08/2002 | CA2436551A1 Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
| 08/08/2002 | CA2436544A1 Ether derivatives useful as inhibitors of pde4 isozymes |
| 08/08/2002 | CA2436535A1 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| 08/08/2002 | CA2436487A1 Methods of inhibiting kinases |
| 08/08/2002 | CA2436418A1 Process for production of nanoparticles and microparticles by spray freezing into liquid |
| 08/08/2002 | CA2436403A1 Anti-rubeola antibody for treating crohn's disease |
| 08/08/2002 | CA2436281A1 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) |
| 08/08/2002 | CA2436266A1 Pyk2 phosphorylation by her3 induces tumor invasion |
| 08/08/2002 | CA2436245A1 Medicament for protection in radiotherapy |
| 08/08/2002 | CA2436209A1 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates |
| 08/08/2002 | CA2436133A1 Receptor selective cannabimimetic aminoalkylindoles |
| 08/08/2002 | CA2436130A1 Substituted indoles and their use as integrin antagonists |
| 08/08/2002 | CA2436092A1 Modified antibodies and methods of use |
| 08/08/2002 | CA2436000A1 An antistress agent |
| 08/08/2002 | CA2435958A1 Pyrimidine compounds and methods for making and using the same |
| 08/08/2002 | CA2435545A1 Synthesis for the preparation of compounds for screening as potential tubulin binding agents |
| 08/08/2002 | CA2434953A1 Protein modification and maintenance molecules |
| 08/08/2002 | CA2434491A1 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| 08/08/2002 | CA2434281A1 An improved in vitro method of culturing mammalian cells for autologous cell implantation/transplantation methods |
| 08/08/2002 | CA2432981A1 Use of fredericamycin a and its derivatives in the treatment of pin1-associated states |
| 08/08/2002 | CA2432867A1 A novel human leucine-rich repeat containing protein expressed predominately in small intestine, hlrrsi1 |
| 08/08/2002 | CA2432642A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 08/08/2002 | CA2431589A1 C-glucosyl ether lipids |
| 08/08/2002 | CA2431559A1 Process for making substituted 8-arylquinolinium benzenesulfonate |
| 08/08/2002 | CA2430653A1 Transfection of human embryonic stem cells |
| 08/08/2002 | CA2427610A1 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 08/08/2002 | CA2426684A1 Inhibitors of prenyl-protein transferase |
| 08/07/2002 | EP1229122A2 Chimeric isoprenoid synthases and uses thereof |
| 08/07/2002 | EP1229045A1 Universal carrier for targeting molecules to Gb3 receptor expressing cells |
| 08/07/2002 | EP1229040A2 Nucleoside monophosphate derivative, a processor for their production and their use as immunosuppressive drugs |
| 08/07/2002 | EP1229034A1 Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes |
| 08/07/2002 | EP1229030A2 Hydrolysis-promoting taxane hydrophobic derivates |
| 08/07/2002 | EP1229024A1 m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM |
| 08/07/2002 | EP1228769A1 Symbiotic regenerative composition |
| 08/07/2002 | EP1228766A1 PYK2 phosphorylation by HER3 induces tumor invasion |
| 08/07/2002 | EP1228759A2 Pharmaceutical compositions containing a taxane having a furyl or thienyl substituted side-chain |
| 08/07/2002 | EP1228755A1 Use of biodegradable microspheres for the delivery of an anticancer agent for the treatment of gliblastoma |
| 08/07/2002 | EP1228373A2 Diagnosis and therapy of cancer using sgp28-related molecules |
| 08/07/2002 | EP1228235A1 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins |
| 08/07/2002 | EP1228234A2 Production of chimeric capsid vectors |
| 08/07/2002 | EP1228224A1 Recombinant attenuated listerias for immunotherapy |
| 08/07/2002 | EP1228222A2 Human transferase molecules |
| 08/07/2002 | EP1228221A2 Human sphingosine kinase gene |
| 08/07/2002 | EP1228210A2 Nuclear matrix proteins, polynucleotide sequences encoding them, and their use |
| 08/07/2002 | EP1228208A2 36p6d5: secreted tumor antigen |
| 08/07/2002 | EP1228203A2 Peptide (virip) which inhibits a circulating virus in humans and the use thereof |
| 08/07/2002 | EP1228202A2 Antisense compositions and cancer-treatment methods |
| 08/07/2002 | EP1228095A1 Modified gp100 and uses thereof |
| 08/07/2002 | EP1228092A1 24 human secreted proteins |
| 08/07/2002 | EP1228089A2 Salt form of a conjugate useful in the treatment of prostate cancer |
| 08/07/2002 | EP1228088A2 Novel traf family proteins |
| 08/07/2002 | EP1228087A1 Antibody catalysis of enantio- and diastereo-selective aldol reactions |
| 08/07/2002 | EP1228084A1 Production of polymorphic forms i and ii of finasteride by complexation with group i or ii metal salts |
| 08/07/2002 | EP1228082A1 29 human secreted proteins |
| 08/07/2002 | EP1228080A2 Compositions and methods for double-targeting virus infections and targeting cancer cells |
| 08/07/2002 | EP1228077A1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities |
| 08/07/2002 | EP1228076A1 A substantially cell membrane impermeable compound and use thereof |
| 08/07/2002 | EP1228073A2 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 08/07/2002 | EP1228072A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 08/07/2002 | EP1228071A1 Pharmaceutically active isoindoline derivatives |
| 08/07/2002 | EP1228070A1 Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 08/07/2002 | EP1228067A1 5-membered n-heterocyclic compounds with hypogylcemic and hypolipidemic activity |
| 08/07/2002 | EP1228063A2 Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
| 08/07/2002 | EP1228061A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| 08/07/2002 | EP1228058A1 Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them |
| 08/07/2002 | EP1228055A1 Dihydroaminobenzo[b]- and [c]furans as retinoid-like agents |
| 08/07/2002 | EP1228054A1 Compounds and their use as cysteine protease inhibitors |
| 08/07/2002 | EP1228047A1 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist |
| 08/07/2002 | EP1228045A2 Heterocyclic cytotoxic agents |
| 08/07/2002 | EP1228044A2 Pyrrolo imidazole derivatives and their use as medicaments |
| 08/07/2002 | EP1228042A2 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 08/07/2002 | EP1228037A1 Compounds having mif antagonist activity |
| 08/07/2002 | EP1228024A1 Novel hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 08/07/2002 | EP1227846A2 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 08/07/2002 | EP1227845A2 Mixture containing rare earths and use thereof |
| 08/07/2002 | EP1227841A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 08/07/2002 | EP1227840A1 Adjuvanted genetic vaccines |
| 08/07/2002 | EP1227838A2 Melanoma vaccine and methods of making and using same |
| 08/07/2002 | EP1227837A1 Method of inducing and/or enhancing an immune response to tumor antigens |
| 08/07/2002 | EP1227833A1 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 08/07/2002 | EP1227828A1 Viruses for the treatment of cellular proliferative disorders |
| 08/07/2002 | EP1227824A1 Transplant/implant device and method for its production |